Medicinova Inc stock is traded at $1.41, with a volume of 18,856. It is up +0.71% in the last 24 hours and down -8.44% over the past month. MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Previous Close:
$1.40
Open:
$1.43
24h Volume:
18,856
Relative Volume:
0.36
Market Cap:
$69.40M
Revenue:
$596.60K
Net Income/Loss:
-$11.72M
P/E Ratio:
-
EPS:
-$0.2386
Net Cash Flow:
-$9.51M
1W Performance:
-2.76%
1M Performance:
-8.44%
6M Performance:
+2.17%
1Y Performance:
-10.19%
1-Day Range:
$1.40$1.43
1-Week Range:
$1.40$1.55
52-Week Range:
$1.22$3.90
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova IncSector
HealthcareIndustry
BiotechnologyPhone
858-373-1500Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS